2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
200 recruiting
4
Rare Diseases
across 7 areas
0
News (30d)
Quiet
ENCell Co., Ltd. is a company with 2 orphan drug designations across 4 rare diseases. Active clinical trials in 1 indication. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Charcot-Marie-Tooth disease | human Wharton¿s jelly-derived mesenchymal stem cells | Des.TrialAppr. |
| Duchenne muscular dystrophy | human Wharton¿s jelly derived mesenchymal stem cells | Des.TrialAppr. |
| multiple system atrophy | - | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
37
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
37
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
5
affecting portfolio